2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1678

Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Abstract Number: 620

Innate Immune Stimulation Triggers Altered IL-1a/b Gene Expression and Experimental Spondyloarthritis in HLA-B27/huβ2m Transgenic Rats
Abstract Number: 802

Inpatient Complications in Patients with Giant Cell Arteritis: Increased Risk of Thromboembolism, Delirium and Adrenal Insufficiency
Abstract Number: 2277

Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends
Abstract Number: 899

Insurance Status and U.S. Region Associated with Placement of Permanent Vascular Access in Dialysis Patients with End-Stage Renal Disease Secondary to Lupus Nephritis
Abstract Number: 986

Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjogren’s Syndrome Pathogenesis
Abstract Number: 1556

Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program
Abstract Number: 1353

Integrating Collection of Rheumatoid Arthritis Disease Activity and Physical Function Scores into an Academic Rheumatology Practice to Improve Quality of Care
Abstract Number: 2477

Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Abstract Number: 1991

Integration of Nailfold Capillary Microscopy and Dermoscopy into the Rheumatology Fellows Curriculum
Abstract Number: 1885

Integrative Omics Profiling Reveals Dysregulated Novel Pathways Mediated By microRNAs and DNA Methylation in Osteoarthritis
Abstract Number: 744

Integrin Inhibitor Modulates Pulmonary Fibrosis in the Reactive Oxygen Species Murine Model of Systemic Sclerosis
Abstract Number: 130

Inter-Rater Reliability of the US-7 Score in a Population of Volunteers: Is a Post-Hoc Analysis of Still Images Comparable to the Dynamic Analysis? Results from the German “Rheuma-Truck” Cohort
Abstract Number: 1798

Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjogren’s Syndrome-like Disease in Mice
Abstract Number: 2045

Interaction Effects Between Genes and Blood Lead Level on a Composite Score of Multiple Joint Symptoms: The Johnston County Osteoarthritis Project

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].